COMPANY

Genmab

FDA-approved therapeutic company Clinical Phase 3

Profile checked Oct 10, 2026

Keywords: Endometrial Cancer Ovarian Cancer Diffuse Large B-Cell Lymphoma Follicular Lymphoma Small Lymphocytic Lymphoma Non-hodgkin Lymphoma Non-small Cell Lung Cancer Triple Negative Breast Cancer Platinum-Sensitive Ovarian Cancer Urothelial Carcinoma Platinum-resistant Ovarian Cancer High-grade B-cell Lymphoma Primary Mediastinal Large B Cell Lymphoma Marginal Zone Lymphoma Colorectal Cancer High Grade Epithelial Ovarian Cancer High Grade Serous Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Cancer Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC) Mesothelioma Breast Adenocarcinoma Hormone Receptor-positive/Her2 Negative Breast Cancer Platinum Sensitive Ovarian Cancer Primary Refractory Ovarian Cancer Uterine Cancer Cervical Cancer Gastrointestinal Cancers PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC R/R AML R/R HR-MDS Acute Myeloid Leukemia Higher-Risk Myelodysplastic Syndrome

68Trials (company is sponsor)

Timeline

2026-11 Trial start Phase 3: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants Wi source ↗
Oct 7, 2026 Trial start Phase 3: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) source ↗
Aug 28, 2026 Trial start Phase 3: Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treat source ↗
Aug 13, 2026 Trial start 1: A Phase 1 Trial of GEN1119 in Participants With Solid Tumors source ↗
Aug 11, 2026 Trial start Phase 3: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) source ↗
Jun 26, 2026 Trial start Phase 3: An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China source ↗
May 11, 2026 Trial start Phase 2: Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers source ↗
Apr 14, 2026 Trial start Phase 1: A Study of GEN1106 in Participants With Solid Tumors source ↗
Apr 7, 2026 Trial start Phase 1: Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors source ↗
Apr 3, 2026 Trial start Phase 3: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer source ↗
Feb 16, 2026 Trial start Phase 1: First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) source ↗
Jan 30, 2026 Trial start Phase 2: Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer source ↗
Nov 28, 2025 Trial start Phase 3: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer source ↗
Nov 18, 2025 Debt Debt: $1.5B (not counted as a raise), announced Nov 18, 2025. Source: company release on GlobeNewswire. source ↗
Jul 25, 2025 Trial start Phase 2: Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibito source ↗
Feb 7, 2025 Trial start Phase 3: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer source ↗
Jan 29, 2025 Trial start Phase 1/Phase 2: A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors source ↗
Nov 25, 2024 Trial start Phase 3: Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) source ↗
Nov 13, 2024 Trial start 1: A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors source ↗
Aug 28, 2024 Trial start Phase 1: Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors source ↗
Aug 13, 2024 Trial start Phase 3: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult source ↗
May 14, 2024 Trial start Phase 1/Phase 2: Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy source ↗
Feb 5, 2024 Trial start Phase 3: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previ source ↗
Jan 3, 2024 Trial start Phase 1/Phase 2: PRO1107 in Patients With Advanced Solid Tumors source ↗
Nov 24, 2023 Trial start Phase 1: A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors source ↗

Showing 25 of 51 dated events.

Upcoming milestones

2027-03 (ESTIMATED) · Phase 2 · A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic F · NCT05451810
2027-06 (ESTIMATED) · Phase 3 · A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone ( · NCT05578976
2027-07 (ESTIMATED) · Phase 1/Phase 2 · Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) · NCT05579366
Jul 30, 2027 (ESTIMATED) · Phase 3 · Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) · NCT06635824
2027-08 (ESTIMATED) · Phase 1 · A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors · NCT06057038
2027-09 (ESTIMATED) · Phase 3 · An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China · NCT07604766
2027-09 (ESTIMATED) · Phase 1/Phase 2 · Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) · NCT04542824
Sep 30, 2027 (ESTIMATED) · Phase 1/Phase 2 · Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) · NCT04663347

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Debt: $1.5B. Last 2 years.

Nov 18, 2025 Debt: $1.5B (not counted as a raise), announced Nov 18, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) Showing 50 of 68

Record	Title	Phase	Status	Start	Primary completion
NCT07775287	Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)	Phase 3	Recruiting	Oct 7, 2026	Mar 30, 2029 (estimated)
NCT05579366	Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)	Phase 1/Phase 2	Recruiting	Dec 7, 2022	2027-07 (estimated)
NCT07564141	Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer	Phase 3	Recruiting	Aug 28, 2026	2029-12 (estimated)
NCT06573294	Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors	Phase 1	Terminated	Aug 28, 2024	Apr 7, 2026 (actual)
NCT07695831	A Phase 1 Trial of GEN1119 in Participants With Solid Tumors	1	Recruiting	Aug 13, 2026	2029-06 (estimated)
NCT07539311	Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers	Phase 2	Recruiting	May 11, 2026	2028-09 (estimated)
NCT07416123	A Study of GEN1106 in Participants With Solid Tumors	Phase 1	Recruiting	Apr 14, 2026	Apr 5, 2029 (estimated)
NCT06635824	Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)	Phase 3	Active, not recruiting	Nov 25, 2024	Jul 30, 2027 (estimated)
NCT07604766	An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China	Phase 3	Recruiting	Jun 26, 2026	2027-09 (estimated)
NCT07288177	Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer	Phase 2	Recruiting	Jan 30, 2026	Nov 22, 2027 (estimated)
NCT07384715	First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)	Phase 1	Recruiting	Feb 16, 2026	Oct 18, 2029 (estimated)
NCT06057038	A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors	Phase 1	Active, not recruiting	Nov 24, 2023	2027-08 (estimated)
NCT03625037	First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma	Phase 1/Phase 2	Active, not recruiting	Jun 26, 2018	2029-01 (estimated)
NCT04663347	Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)	Phase 1/Phase 2	Active, not recruiting	Nov 3, 2020	Sep 30, 2027 (estimated)
NCT04542824	Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)	Phase 1/Phase 2	Active, not recruiting	Aug 20, 2020	2027-09 (estimated)
NCT07702032	Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)	Phase 3	Recruiting	Aug 11, 2026	2029-07 (estimated)
NCT07166094	Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer	Phase 3	Recruiting	Nov 28, 2025	2029-08 (estimated)
NCT04623541	Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome	Phase 1/Phase 2	Active, not recruiting	Nov 25, 2020	2027-12 (estimated)
NCT07225270	Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy	Phase 3	Recruiting	Apr 3, 2026	2028-10 (estimated)
NCT07859215	Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer	Phase 3	Not yet recruiting	2026-11	2030-03 (estimated)
NCT06984328	Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)	Phase 2	Terminated	Jul 25, 2025	May 15, 2026 (actual)
NCT06619236	Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer	Phase 3	Active, not recruiting	Feb 7, 2025	Aug 18, 2026 (actual)
NCT05117242	Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer	Phase 2	Terminated	Oct 27, 2021	Dec 2, 2024 (actual)
NCT05451810	A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma	Phase 2	Active, not recruiting	Aug 17, 2022	2027-03 (estimated)
NCT05201248	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma	Phase 1/Phase 2	Active, not recruiting	Mar 10, 2022	2026-09 (estimated)
NCT05206357	Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab	Phase 1	Active, not recruiting	Oct 4, 2022	2028-11 (estimated)
NCT05578976	A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 3	Active, not recruiting	Feb 8, 2023	2027-06 (estimated)
NCT07387068	Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors	Phase 1	Recruiting	Apr 7, 2026	2031-01 (estimated)
NCT03917381	GEN1046 Safety Trial in Patients With Malignant Solid Tumors	Phase 1/Phase 2	Terminated	May 14, 2019	Apr 1, 2025 (actual)
NCT05491317	A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors	Phase 1/Phase 2	Terminated	Mar 8, 2023	Aug 11, 2025 (actual)
NCT06391775	Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy	Phase 1/Phase 2	Terminated	May 14, 2024	Nov 20, 2025 (actual)
NCT04083599	GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors	Phase 1/Phase 2	Active, not recruiting	Sep 17, 2019	Dec 30, 2025 (actual)
NCT06191744	Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma	Phase 3	Active, not recruiting	Feb 5, 2024	2037-11 (estimated)
NCT05180474	GEN1047 for Solid Tumors - First in Human (FIH) Trial	Phase 1/Phase 2	Terminated	Dec 13, 2021	Mar 25, 2026 (actual)
NCT06685068	A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors	1	Terminated	Nov 13, 2024	Mar 30, 2026 (actual)
NCT05409066	Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma	Phase 3	Active, not recruiting	Sep 20, 2022	2029-12 (estimated)
NCT05283720	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma	Phase 2	Active, not recruiting	Jun 14, 2022	2032-11 (estimated)
NCT05660967	Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma	Phase 2	Terminated	Mar 6, 2023	Jun 10, 2026 (actual)
NCT06171789	PRO1107 in Patients With Advanced Solid Tumors	Phase 1/Phase 2	Terminated	Jan 3, 2024	Aug 18, 2025 (actual)
NCT04628494	A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)	3	Active, not recruiting	Jan 13, 2021	Oct 13, 2025 (actual)
NCT04824794	GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies	Phase 1/Phase 2	Terminated	Mar 9, 2021	Jun 30, 2025 (actual)
NCT07226752	A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China	Phase 3	Active, not recruiting	Oct 8, 2022	Oct 13, 2025 (actual)
NCT06508658	A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Active, not recruiting	Aug 13, 2024	2028-03 (estimated)
NCT05721222	Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)	Phase 1/Phase 2	Terminated	Mar 15, 2023	Nov 5, 2025 (actual)
NCT06771921	A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors	Phase 1/Phase 2	Terminated	Jan 29, 2025	Jun 11, 2025 (actual)
NCT05586321	Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors	Phase 1	Completed	Oct 24, 2022	Oct 23, 2025 (actual)
NCT06018129	A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma	Phase 1/Phase 2	Terminated	Sep 21, 2023	Feb 5, 2025 (actual)
NCT04937153	GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies	Phase 1	Completed	Jun 15, 2021	Oct 1, 2024 (actual)
NCT05435339	A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy	Phase 1/Phase 2	Terminated	Oct 4, 2022	May 24, 2024 (actual)
NCT04358458	First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas	Phase 1/Phase 2	Terminated	Mar 13, 2020	Nov 21, 2022 (actual)